AR and Familial prostate cancer: By applying the prostate reference epigenome to functionally annotate genetic variants associated with prostate cancer, we identified two GWAS SNPs in prostate enhancers that may disrupt androgen receptor (AR) binding and the target gene regulatory network, thereby providing a mechanistic hypothesis regarding genetic predisposition for the disease.